Off Script: A Pharma Manufacturing Podcast

By Pharma ManufacturingNews Business News

Off Script: A Pharma Manufacturing Podcast episodes

September 16, 2025 Editor’s (re)View: It matters if Big Pharma is fudging its US investment numbers
Large biopharma companies in recent months have pledged billions of dollars in capital expenditures for U.S. manufacturing and R&D facilities. What if it’s not accurate?
Greg Slabodkin

Read by Brittany Duncan

https://www.pharmamanufacturing.com/editors-review/article/55314470/editors-review-it-matters-if-big-pharma-is-fudging-its-us-investment-numbers
4 min
September 10, 2025 Can CDMOs keep up with the increasing demand for GLP-1 medications?
The wildly popular drugs, prescribed for weight loss and type 2 diabetes, are putting a strain on the capabilities of contract development and manufacturing organizations.
Greg Slabodkin

Read by Brittany Duncan

https://www.pharmamanufacturing.com/sector/contract-manufacturing/article/55314756/can-cdmos-keep-up-with-the-increasing-demand-for-glp-1-medications
6 min
August 26, 2025 FDA’s program to speed up US manufacturing buildouts is short on detail
While the agency’s PreCheck regulatory framework is a good first step, it remains to be seen whether the program boosts U.S. drug manufacturing, says former FDA official.
Greg Slabodkin

Read by Brittany Duncan

https://www.pharmamanufacturing.com/all-articles/article/55309136/fdas-program-to-speed-up-us-manufacturing-buildouts-is-short-on-detail
6 min
August 19, 2025 New Jersey remains hot life sciences hub despite macroeconomic, funding headwinds
The Garden State, called the “medicine chest” to the world, continues to show robust activity with life sciences firms accounting for nearly 30% of all Q2 leasing activity.
Greg Slabodkin

Read by Brittany Duncan

https://www.pharmamanufacturing.com/all-articles/article/55308250/new-jersey-remains-hot-life-sciences-hub-despite-macroeconomic-funding-headwinds
6 min
July 15, 2025 Critical Timing: Hikma’s Billion-Dollar U.S. Investment
Generics, which make up approximately 90% of prescription volume in the U.S., are produced primarily in India as Hikma looks to onshore production of these critical drugs.
Greg Slabodkin

Read by Brittany Duncan

https://www.pharmamanufacturing.com/all-articles/article/55302441/hikmas-planned-1b-us-investment-comes-at-critical-time-for-generic-medicines-supply
7 min
July 01, 2025 Editor’s (re)View: Is the biopharma industry’s glass half empty or half full?
While macroeconomic uncertainty weighs on the sector, there are glimmers of hope in some areas of pharmaceutical outsourcing and services.
Greg Slabodkin

Read by Brittany Duncan

Read Article Here: https://www.pharmamanufacturing.com/editors-review/article/55299879/editors-review-is-the-biopharma-industrys-glass-half-empty-or-half-full
5 min
June 26, 2025 Life sciences manufacturers overwhelmingly embrace smart tech: global survey
Smart manufacturing is “nearly universal” with 95% of manufacturers saying they are using or evaluating smart technology, according to a new survey from Rockwell Automation.
Greg Slabodkin

Read by Brittany Duncan
5 min
June 23, 2025 Flow state: The evolving shape of continuous manufacturing
While the pharmaceutical industry has been slow to adopt continuous manufacturing, it appears to be gaining momentum.
Greg Slabodkin

Read by Brittany Duncan

Enjoy the article Here: https://www.pharmamanufacturing.com/all-articles/article/55295669/flow-state-the-evolving-shape-of-continuous-manufacturing
16 min
May 12, 2025 [Solutions Spotlight] Hydrogenation: Bridging the gap between nitration and phosgenation
Hydrogenation can serve as a critical link in chemical synthesis, particularly between nitration and phosgenation. When integrated strategically, it helps enable safer, more efficient production processes.
To better understand this connection, we spoke with Dr. Luca Mantilli, R&D Chemist at Valsynthese, the fine chemicals division of Société Suisse des Explosifs Holding (SSE). Dr. Mantilli discussed how hydrogenation was implemented to bridge the gap between two of the company’s core hazardous chemistries: nitration and phosgenation.
Learn more about Valsynthese: https://www.valsynthese.ch/
19 min
April 30, 2025 Editor’s (re)View: BMS, Merck, Roche see manufacturing flexibility as key to dealing with tariffs
The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.
5 min

About Off Script: A Pharma Manufacturing Podcast

From the publisher's feed

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online…